Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
Context Therapeutics received written notice from Nasdaq on July 29, 2026, that it failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until January 25, 2027, to regain compliance or faces potential delisting, with the possibility of a second 180-day cure period if it meets Capital Market listing standards. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-31
Item 8.01
Nocera regained compliance with Nasdaq Listing Rule 5550(a)(2) following a minimum bid price deficiency, having previously failed to maintain the $1.00 minimum closing bid price (notified February 2, 2026). The July 28, 2026 Compliance Notice confirms the company satisfied the 15 consecutive business days requirement and Nasdaq has closed the matter.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-30
EX-99.1
The exhibit announces resumption of trading after a trading halt imposed by Nasdaq on June 4, 2026, under halt code "T12 — Additional Information Requested by Nasdaq" pursuant to Nasdaq Listing Rule 5250(a). Although the halt has been lifted and trading resumes July 31, 2026, the disclosure documents a material delisting risk event—the Company faced Nasdaq scrutiny regarding compliance with listing standards, including minimum bid price requirements (evidenced by two share consolidations undertaken to maintain compliance with Nasdaq Listing Rule 5550(a)(2)). The Company's responses to Staff inquiries and the Staff's confirmation of no further questions indicate resolution of the immediate threat, but the underlying compliance pressures and multiple share consolidations signal material listing-qualification concerns that would affect a reasonable investor's assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-30
Item 3.01
Lument Finance Trust received notice from the NYSE on July 24, 2026, that it failed to comply with Section 802.01C of the NYSE Listed Company Manual because the average closing price of its common stock was below $1.00 over a consecutive 30 trading-day period. The company has a six-month cure period ending January 24, 2027, and is considering alternatives such as a reverse stock split to regain compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-30
Item 3.01
The Company received notice from Nasdaq on July 24, 2026 that it has regained compliance with the Bid Price Rule but remains subject to a one-year Discretionary Panel Monitor period. While the immediate delisting threat has been lifted, the filing explicitly discloses that failure to maintain compliance during the monitor period will result in a Delist Determination Letter with no opportunity for a compliance plan, and states "there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq." This is a material disclosure of continued delisting risk and heightened monitoring status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-30
Item 5.03
While the filing formally discloses a reverse stock split under Item 5.03, the substance reveals acute delisting risk. SCWorx is implementing the 1-for-12 reverse split specifically to satisfy Nasdaq's minimum bid price requirement ($1.00 per share by August 28, 2026), and the disclosure explicitly warns that the split will create additional Nasdaq deficiencies (publicly held shares below 500,000 minimum, market value of publicly held shares below $1,000,000) that the company may be unable to cure. The filing states that failure to maintain $1.00 bid price for 30 consecutive days within one year will trigger automatic delisting without a compliance period, and that the company's ability to use further reverse splits is "substantially limited." This is a material delisting threat, not a routine bylaw amendment.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-30
EX-99.1
SunCar received a Nasdaq notification on July 27, 2026, that its Class A ordinary shares failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days (June 10–July 24, 2026). The company has 180 calendar days until January 25, 2027, to regain compliance; failure to do so could result in delisting. The press release explicitly discusses the delisting determination process and the company's obligation to monitor compliance, making this a clear delisting-risk disclosure under Nasdaq Listing Rule 5810.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-30
Item 3.01
Keen Vision Acquisition Corp. received a notice from Nasdaq on July 27, 2026, indicating that its securities (units, ordinary shares, and warrants) will be suspended and delisted from The Nasdaq Global Market effective August 3, 2026, due to non-compliance with Nasdaq IM-5101-2 (failure to complete a business combination within 36 months of IPO), the minimum publicly held shares requirement, and the minimum holders requirement. The company has confirmed it will not appeal and will file Form 25-NSE with the SEC to remove the securities from listing. This is a material delisting event that directly affects the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-30
Item 3.01
Genprex received a Nasdaq delisting notice on June 10, 2026 for failure to maintain the $1.00 minimum bid price requirement. Although the Nasdaq Hearings Panel granted an exception on July 29, 2026 allowing continued listing through December 7, 2026 subject to strict conditions, the company faces material delisting risk if it fails to maintain compliance with the bid price requirement during this cure period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-30
Flux Power received notice from Nasdaq on July 24, 2026 that its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). The filing explicitly states that if the company does not regain compliance by the end of the compliance period (or an additional 180-day period if eligible), "the Company's common stock will be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-30
EX-99.1
Fenbo received a Nasdaq notification on July 27, 2026 that it failed to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days until January 25, 2027 to regain compliance or face potential delisting. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-30
Item 3.03
Lexaria Bioscience effected a 1-for-15 reverse stock split to restore compliance with NASDAQ Capital Market's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2), addressing delisting risk during its 180-day compliance period. The company anticipates requesting a NASDAQ hearing to appeal any delisting notification.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-29
Item 8.01
The disclosure explicitly addresses Nasdaq compliance with the stockholders' equity requirement and warns that "if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to future delisting." This is a clear notice of delisting risk tied to failure to satisfy a continued listing rule, which is the defining characteristic of the delisting_risk event type.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-29
Item 8.01
The filing discloses that PowerCompute regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) after receiving a delisting notice on January 7, 2026, for failing to maintain the bid price for 30 consecutive business days. Although the company has now cured the deficiency and Nasdaq has closed the matter, the core event disclosed is the resolution of a delisting risk that threatened the company's continued listing on the Nasdaq Capital Market. This is material to investors as listing status directly affects liquidity, credibility, and market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-29
Item 8.01
SCWorx was delisted from Nasdaq on April 14, 2026 for failing to maintain the minimum bid price of $1 per share, but successfully appealed and received conditional continued listing on June 17, 2026 subject to completing a reverse stock split and achieving compliance with the bid price rule by August 28, 2026. The filing discloses the delisting event, the appeal process, and the conditions for maintaining listing—core delisting-risk disclosure. The company has received partial compliance confirmation as of July 24, 2026, but faces material uncertainty about achieving full compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-29
Item 3.01
The Company received a deficiency letter from Nasdaq on July 22, 2026, notifying it that its market value of listed securities (MVLS) closed below the $35 million threshold required under Nasdaq Listing Rule 5550(b)(2) for 30 consecutive business days. The Company has until January 19, 2027 to regain compliance, and failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-29
Item 8.01
The filing discloses a nonbinding letter of intent to exchange debt and waive token rights specifically to "cure the Company's minimum stockholders' equity requirement deficiency under Nasdaq Listing Rule 5550(b)(1)" and "bring the Company back into compliance with Nasdaq's continued listing requirements." The Company previously announced this deficiency in a June 12, 2026 8-K, indicating an imminent delisting risk that the proposed transaction is designed to remediate. This is a material disclosure of the registrant's failure to satisfy a continued listing rule.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-29
The filing discloses that on July 21, 2026, Fly-E Group received a delinquency notification from Nasdaq's listing qualifications staff for failure to meet the periodic filing requirement under Listing Rule 5250(c)(1). Although the company subsequently cured the deficiency by filing its Form 10-K on July 23, 2026, and the matter was closed, the initial notice of non-compliance with continued listing standards constitutes a delisting risk event material to investors. The disclosure of the delinquency notice itself—even though remedied—is the core material event being reported.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-29
EX-99.1
Youlife received a Nasdaq notification letter dated July 27, 2026, indicating non-compliance with the minimum bid price requirement (Rule 5550(a)(2)) because its ADS closing bid price has been below US$1.00 for 30 consecutive business days. Although the notification does not result in immediate delisting, the Company has 180 calendar days (until January 25, 2027) to regain compliance or face potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-29
EX-99.1
The exhibit announces a voluntary transfer of Collective Mining's U.S. stock exchange listing from NYSE American to Nasdaq Global Select Market, effective August 11, 2026. While framed positively as an upgrade to "the highest tier of the Nasdaq," this constitutes a material change in listing venue under Item 3.01 (Changes in and Acquisitions or Dispositions of Assets). The transfer involves delisting from one exchange and listing on another, which materially affects the registrant's capital markets presence and investor accessibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-29
Item 3.01
Loop Industries received two separate Nasdaq notices on July 24 and July 27, 2026, indicating non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement and the minimum bid price requirement. The company has 180 calendar days to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-29
Celularity received notice from Nasdaq on July 23, 2026, that it no longer complies with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) because its Class A common stock closing bid price fell below $1.00 per share for 30 consecutive business days. The company has 180 calendar days until January 19, 2027, to regain compliance or face potential delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-29
HWH International received a Nasdaq deficiency notice on May 29, 2026 for failing to meet the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1), with reported equity of only $2,078,220. Although Nasdaq granted an extension on July 24, 2026 to regain compliance by August 31, 2026, this is a material delisting risk disclosure. The filing explicitly addresses the company's non-compliance with continued listing standards and the remedial actions required to avoid delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-29
Item 3.01
LiveWire received a deficiency notice from the NYSE on July 23, 2026, for failure to maintain a minimum average closing share price of $1.00 over a consecutive 30 trading-day period, triggering non-compliance with Section 802.01C of the NYSE Listed Company Manual. The company has six months to regain compliance or face delisting procedures.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-28
The 6-K discloses that BGM Group Ltd. previously received a Nasdaq non-compliance notice on February 26, 2026 for failure to file its Form 20-F annual report timely (Nasdaq Listing Rule 5250(c)(1)). The Company has now regained compliance by filing the 2025 Annual Report on July 21, 2026, and received confirmation from Nasdaq on July 24, 2026. This disclosure directly addresses a delisting risk — the threat of removal from listing due to failure to meet continued listing standards — and its resolution. Material to investors as it affects the Company's continued trading eligibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-28
Item 8.01
The Company received a notice from Nasdaq on May 22, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q. The disclosure explicitly describes the delisting risk: Nasdaq may not accept the Company's compliance plan, and there is no assurance the Company will regain compliance within any extension period. This is a classic delisting-risk disclosure under Item 3.01 (though filed under Item 8.01), materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-28
The 6-K discloses that CCH Holdings has regained compliance with Nasdaq's Minimum Bid Price Rule (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on February 3, 2026. The company's stock price had fallen below $1.00 for 30 consecutive business days, triggering delisting risk. The July 27, 2026 letter confirms the company has cured the deficiency by maintaining a closing bid price of $1.00 or greater for at least 10 consecutive business days, resolving the delisting threat. This is material because it directly addresses a prior delisting risk that would have affected investor assessment of the company's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-28
EX-99.1
Blue Gold received a Nasdaq notification that it failed to maintain the minimum Market Value of Publicly Held Shares (MVPHS) of $15 million for 30 consecutive business days. The company has 180 calendar days (until January 20, 2027) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Nasdaq Listing Rule 5810(c)(3)(D), materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-28
SCWorx received a Nasdaq deficiency notice on July 24, 2026, stating that its Market Value of Publicly Held Shares (MVPHS) fell below the $1 million minimum required by Nasdaq Listing Rule 5550(a)(5). The company has 180 calendar days through January 20, 2027 to regain compliance, with explicit language that "there can be no assurance that the Company will regain compliance with the MVPHS Requirement, or that the Company's securities will remain listed on Nasdaq." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-28
Item 8.01
The disclosure centers on Nasdaq's conditional grant of continued listing contingent on the Company demonstrating compliance with the minimum bid price rule ($1.00 per share) by August 15, 2026. The Panel retains jurisdiction through November 23, 2026, with an explicit threat of immediate delisting if the Company fails to maintain compliance during that period. This is a classic delisting-risk disclosure under Item 3.01 framework, though disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-28
The filing discloses Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule. Blink Charging received a second notice from Nasdaq on July 28, 2026, confirming that while the company has not regained compliance with the Nasdaq Minimum Bid Price Rule ($1.00 per share), it has been granted an additional 180-calendar-day cure period until January 25, 2027. The company faces delisting if it cannot demonstrate compliance by that date, though it may appeal to a Nasdaq Hearings Panel. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-28
Item 1.02
The filing discloses that Nuvve's common stock was delisted from Nasdaq effective July 24, 2026, triggering automatic termination of a $25 million committed equity facility (ELOC Agreement). While Item 1.02 nominally addresses termination of a material agreement, the salient event is the delisting itself—a terminal listing event that materially impairs the company's access to capital markets and signals substantial financial distress. The delisting is the triggering cause and the primary material disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-27
Item 3.01
Trading of the Company's Common Stock on Nasdaq was suspended on July 21, 2026, and the Company requested removal from listing. The Company intends to file Form 15 to terminate registration under Section 12 of the Exchange Act and suspend reporting obligations, a direct consequence of the merger completion.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-27
The filing discloses that Maison Solutions regained compliance with Nasdaq Listing Rule 5620(a) after receiving a non-compliance notice on May 6, 2026, for failing to hold an annual meeting within one year of fiscal year-end. The company held its annual meeting on July 22, 2026, and Nasdaq confirmed on July 24, 2026, that compliance was restored and "the matter is now closed." This is a delisting-risk event because it documents the company's prior non-compliance with a continued listing requirement and its subsequent remediation, which is material to investors assessing listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-27
The filing discloses a final delisting decision from Nasdaq effective July 27, 2026, following the Company's non-compliance with periodic reporting requirements and minimum bid price standards. The Nasdaq Hearings Panel determined to delist Vestand Inc.'s Class A Common Stock from The Nasdaq Capital Market, with the stock subsequently trading on the OTC Pink Limited Market. This is a material event that directly affects the registrant's listing status and investor access to the security.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-27
Item 3.01
AMASS Brands received notification letters from Nasdaq on July 22, 2026, stating non-compliance with continued listing requirements due to market value of listed securities (MVLS) falling below $50 million and market value of publicly held shares (MVPHS) falling below $15 million. The company has 180 calendar days until January 19, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-27
Item 3.01
Nasdaq notified Nexalin on July 24, 2026 that the Company's securities will be delisted from The Nasdaq Capital Market due to failure to regain compliance with the Minimum Bid Price Requirement ($1.00 per share) and ineligibility for a second compliance period due to insufficient stockholders' equity ($5,000,000 minimum). The Company's securities are scheduled for suspension on August 4, 2026, with a Form 25-NSE to be filed unless the Company successfully appeals to a Nasdaq Hearings Panel by July 31, 2026. This is a material delisting notice under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-24
Item 8.01
The Company received notification from the NYSE that it has regained compliance with continued listing standards after previously falling below the minimum market capitalization and stockholders' equity requirements of Section 802.01B. While this is technically a positive resolution, the disclosure centers on the Company's prior non-compliance status and the conditional nature of its reinstatement—the NYSE explicitly warns that falling below standards again within 12 months could trigger trading suspension procedures. This is a material delisting-risk disclosure because it reveals the Company was in jeopardy of delisting and remains under heightened monitoring.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Liminatus Pharma failed to regain compliance with Nasdaq's minimum bid price rule ($1 per share) and is ineligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with no assurance the company can regain compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Oncolytics Biotech received formal notice from Nasdaq on July 20, 2026, that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-calendar-day compliance period ending January 19, 2027. The filing explicitly discloses the delisting risk and the conditions under which the company's stock would be subject to delisting if it fails to regain compliance. This is a textbook delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-24
Item 3.01
Taylor Morrison notified the NYSE of the anticipated completion of the Berkshire Hathaway merger and requested suspension of trading and delisting of TMHC Common Stock from the NYSE, effective August 3, 2026. The company intends to file Form 15 to terminate registration under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Invivyd received a deficiency letter from Nasdaq on July 23, 2026, notifying the company that its stock bid price closed below the $1.00 minimum for 30 consecutive business days, triggering Nasdaq Listing Rule 5450(a)(1). The company has until January 19, 2027 to regain compliance or faces potential delisting, with the possibility of a second compliance period only if it transfers to the Nasdaq Capital Market. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 99%
filed 2026-07-24
Item 3.01
FibroBiologics received a Staff Determination from Nasdaq on July 22, 2026, notifying the company of its determination to delist the company's securities from The Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2). The company's bid price closed below $1.00 for 30 consecutive business days (June 8–July 21, 2026) and is ineligible for the standard 180-day compliance period due to a prior reverse stock split. Unless the company appeals by July 29, 2026, delisting and suspension are scheduled for July 31, 2026. This is a quintessential delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Odyssey Marine received notice from Nasdaq on July 21, 2026 that it failed to satisfy the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has until January 19, 2027 to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Standard BioTools received a formal notice from Nasdaq on July 22, 2026, indicating failure to meet the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days (until January 19, 2027) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued listing status and trading viability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
The Company received notice from the NYSE on July 24, 2026, of non-compliance with Section 802.01C of the NYSE Listed Company Manual due to its average closing stock price falling below $1.00 over a consecutive 30 trading-day period, triggering a six-month cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-24
EX-99.1
FangDD received a Nasdaq deficiency notification on July 22, 2026, for failure to maintain the minimum bid price of US$1 per share for 30 consecutive business days. The company has been granted a 180-day compliance period until January 19, 2027, to regain compliance or face potential delisting. This is a material disclosure under Item 3.01 (Delisting Risk) as it directly threatens the company's continued listing on Nasdaq and would significantly affect investor assessment of the registrant's status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-07-24
The 6-K discloses that Haoxin Holdings has failed to regain compliance with Nasdaq's minimum bid price requirement ($1.00 per share) during the first 180-calendar-day cure period and has been granted an additional 180-day extension until December 14, 2026. The filing explicitly warns that failure to regain compliance within this period will result in delisting notice, with only an appeal right to a Nasdaq hearings panel offering uncertain relief. This is a material delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-24
The Company discloses that the NYSE has determined to commence delisting proceedings for its warrants (ticker VLNW) effective July 24, 2026, based on "abnormally low selling price" under NYSE Listed Company Manual Section 802.01D. Trading in the warrants will be suspended, though the ordinary shares (VLN) remain listed. This is a delisting notice that materially affects the status of a security class.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 87%
filed 2026-07-24
Item 3.03
Faraday Future implemented a 1-for-150 reverse stock split as a proactive risk management measure to avoid Nasdaq delisting, which would be triggered if the stock price fell to $0.10 or below for 10 consecutive trading days. The company disclosed that its closing bid price had approached this critical threshold, and the reverse split was designed to safeguard the Nasdaq listing and preserve liquidity and access to capital.
View raw filing on EDGAR →